Handling a high-risk HIPAA breach

Veronika Valdova • Oct 31, 2019

Published October 31, 2019

Part of scenarios for patient privacy crisis management 


Every hospital encounters patients, who for the reason of their social circumstances, dependent status, personal characteristics, or the nature of their condition, are more vulnerable than the general population. While compliance with HIPAA is indeed important, because of the potential to inflict significant liability on the hospital resulting from compliance failure, it should not be the only consideration when caring for vulnerable patients. Mere compliance with the minimum requirements of HIPAA does not guarantee the safety of vulnerable patients. In the case study scenario, the hospital emergency department in a small town admitted a 15-year-old female with emergency labor. After delivery in the emergency room, the mother and the baby were moved to Obstetrics and Neonate. Despite appropriate care, the infant presented with multiple medical problems, which may or may not be resolved in the future. A nurse, who took care of the young mother, inadvertently disclosed the patient’s identity and condition to her young daughter, who found her mother's phone and managed to spread the news in all high schools in the area by the following day. The 15-year-old managed to hide her pregnancy from her family. To complicate matters, the young mother’s mother and aunt work in the same hospital. 


HIPAA assessment 

The Health Insurance Portability and Accountability Act of 1996 (HIPAA) required the Secretary of the U.S. Department of Health and Human Services (HHS) to develop regulations protecting the privacy and security of certain health information. The HIPAA Privacy Rule sets national standards for the protection of personal health information against unauthorized disclosure. The Privacy Rule can be found at 45 CFR Part 160, and 45 CFR Part 164, Subparts A and E. The standards, requirements, and implementation specifications apply to health plans, healthcare clearinghouses, and healthcare providers and their business associates. The Security Rule sets standards for protecting electronic health information. Enforcement of the regulation is the responsibility of the Office for Civil Rights (OCR) that is part of HHS. In this case study, the nurse disclosed personal health information, including the full identifier and the patient’s medical condition to an unauthorized individual. A nurse, as an employee of a covered entity, would indeed be subject to obligations under HIPAA. The Site Privacy Officer’s concerns should be the facilitation of an investigation and risk of harm assessment. If a Breach is substantiated and notification is required, the Site Privacy Officer shall notify each individual whose PHI has been accessed, acquired, used, or disclosed as a result of the Breach. In cooperation with other hospital functions, the Site Privacy Officer shall determine what additional external notifications should be made. In this case, it may be necessary to notify local law enforcement if there is a reason to believe the minor’s pregnancy was the result of abuse, neglect, or domestic violence. 


A breach or not? 

Breach means the acquisition, access, use, or disclosure of protected health information in a manner not permitted under subpart E, which compromises the security or privacy of PHI. To prevent unauthorized access to text messages that contain patient health information, the messages must use encryption for data at rest and in motion. Encryption makes the information inaccessible to users who are not authorized to access the information, especially when the device is borrowed, lost, or stolen (providertech, 2020). Breach excludes unintentional acquisition, access, or use of PHI by a person acting under the authority of a covered entity, or inadvertent disclosure between employees of the same covered entity, as long as this information does not spread any further. Breach also excludes disclosures made to unauthorized persons who would not be reasonably able to retain such information. Any other acquisition, access, use, or disclosure of PHI not permitted under subpart E is considered a breach [45 CFR 164.402]. Based on this definition, the incident indeed constitutes a breach of personal health information that does not fall under any of the exclusions. In the event of an impermissible use or disclosure of unsecured PHI, the covered entity is obligated to conduct a risk assessment. Breach notification is necessary for all situations where PIH has been compromised. Breach notification is not required if the covered entity demonstrates that there is a low probability that PHI has been compromised. In this particular case, there is no doubt PHI has been compromised since the information reached all four high schools in the area by the following day. 


Breach notification 

The HIPAA Breach notification rule [45 CFR 164.400-414] requires covered entities to report breaches of health information that have not been rendered unusable, unreadable, or indecipherable. Notification of the Breach has to be provided to the affected individuals, the Secretary, and in certain circumstances, to the media. In this instance, the hospital would have to report the Breach to the patient and to the Secretary within 60 days following the discovery of the Breach. The notification must include a description of the Breach and the information involved, and steps the individuals should take to protect themselves from potential harm. Besides, the hospital should include a brief description of what it is doing to investigate the breach, mitigate the harm, and prevent further breaches, as well as contact information such as a toll-free number. To notify the Secretary, the hospital shall submit the information via an electronic form that is available on the OCR website. 


Risk of Harm Assessment 

In January 2013, the Risk of Harm standard was dropped from the final HIPAA Omnibus Rule. The initial rule stated that a breach does not occur unless the access, use or disclosure poses "a significant risk of financial, reputational, or other harm to an individual." It was up to the covered entities to decide whether the harm standard applies or not. The new rule assumes that all impermissible PHI disclosures are reportable (HHS, 2013). However, risk assessment conducted by the hospital shall not be limited to HIPAA compliance obligations. Risk is the probability that a vulnerability will be threatened, resulting in an adverse consequence. The hospital has to consider the potential harm to the affected patient as well as liabilities for the hospital and potential disruption of its own business operations. 


The patient

The case study represents a myriad of ethical and legal problems, in addition to HIPAA compliance. These concerns include the fact that the patient is an unemancipated minor, that her parents were unaware of her condition until birth, and that the pregnancy may have been the result of rape or incest. The consequences of such disclosure in a small town are easy to imagine. Whilst the general acceptance of unwed and underage mothers and offspring conceived out of traditional boundaries of formal marriage depends on location, time, and culture, some patterns are universal in nature and only vary in extent. A teenage mother and a child of uncertain parentage, especially if ill or disabled, are likely to face severe repercussions and lifelong shunning even in the most benign environments. Young mothers may be forced to give up their newborn babies and become themselves subject to retaliation from angry relatives, including the risk of violent death. According to RAINN, the overwhelming majority of victims of sexual abuse know the perpetrator. Even more disturbingly, in 80% of perpetrators were a parent (RAINN, 2013). 


Josephson (2016), in her book “Rethinking sexual citizenship” (Josephson, 2016) discusses in detail the causes and consequences of early motherhood, including various societal ills connected to the phenomenon of teenage motherhood, both real and perceived. Teenage sexual activity is considered a deviancy and a threat to public order, and as such, it is subject to widespread public shaming (pp. 82-84).  The experiences of teenage mothers can be extremely distressing due to public shaming, shunning, rejection by the community and the family, and absence of elementary support. Even worse, children are often deprived of many opportunities later in their lives because of biases and prejudices; they have to grow up with (Odyssey, 2016). 


According to “Report on Exploratory Study into Honor Violence Measurement Methods”, honor violence seems to be rare in the United States and apparently limited to ethnic minorities mainly from South East Asia. These cultures do not view honor violence as a crime, and the victims or potential victims are unlikely to report victimization because of fear of repercussions from their own family. These cultures defend honor violence as a means to maintain or regain the reputation and social standing of a family by female members who violate the community’s traditions and norms, should it be sexually inappropriate behavior or disobedience (Helba, Bernstein, Leonard and Bauer, 2014). Other cultures find it appropriate to murder the infant whilst preserving the life of the female. Hungary, a country in Eastern Europe, is an example of a culture where infanticide is generally acceptable, although not legal, mechanism of restoring family honor (Journeyman’s Pictures, 2016). The risks to the mother and the infant following such disclosure are grave, and depending on circumstances, and cultural and ethnic background can include retaliation, infanticide, and honor violence.


The Infant

Genetic testing of the infant may be warranted to confirm paternity and exclude or confirm the pregnancy was the result of an incestuous relationship. Whether such a test would or would not be permissible and what authorization is required to conduct such tests is a delicate question that requires careful professional judgment, both medical and legal. Genetic screening without parental consent is subject to much controversy, and New Act Newborn Screening Saves Lives Reauthorization Act of 2014 includes the requirement of parental consent for the screening of newborn babies with deadly yet treatable conditions (National Institutes of Health, 2015). The quality and speed of newborn screening programs vary from state to state (Gabler, 2013).  Whelan (2013) argues that the main concern of privacy advocates and patient advocacy groups was not the initial screening itself but indefinite retention of genetic material for undisclosed uses, potentially resulting in tangible harms in the future such as employment discrimination and insurance coverage (Whelan, 2013). 


The American Society of Human Genetics (ASHG, 2015) published a position statement in which it clarified its stance on genome-scale, carrier, and newborn results, and covered a variety of conditions and circumstances including incest. While parental consent is required under most circumstances, clinician’s judgment can override the lack of parental consent "when there is strong evidence that a secondary finding has urgent and serious implications for a child's health or welfare, and effective action can be taken to mitigate that threat". In this instance, the healthcare provider should be able to perform genetic testing even without parents’ consent. 


Mitigation of adverse consequences


Steps relating to the protection of the young mother and the infant shall be taken with full consideration of the benefits and risks of available options and possible solutions.


Personal representative

With respect to use or disclosure, 45 CFR Part 160 does not preempt State Law in regards to disclosure of protected health information about a minor to a parent [45 CFR 160.202(2)]. However, in this particular instance, the disclosure of the minor’s condition may not be in the best interest of the young mother and her newborn child. First, the minor’s parents or legal representatives were supposedly unaware of their daughter’s pregnancy. This fact itself should trigger hospital procedures for care for vulnerable minors, including potential victims of rape, incest, sexual abuse, parental neglect, domestic violence or human trafficking. A minor does not become an adult by virtue of becoming pregnant and giving birth. Regardless of the potential Breach, determining who is the patient’s legal representative, and making sure, that she does have an appropriate one, would be the most important first step. 


A covered entity may elect not to treat a person as the personal representative of an individual if the reason to believe that the individual may be subjected to domestic violence, abuse or neglect by such person, or treating such person as the personal representative could endanger the individual [45 CFR 164.502 (g)(5)(i)(A)-(B)]. The hospital has the option to exercise its professional judgment and decide not to treat the person as the individual’s personal representative [45 CFR 164.502 (g)(ii)].  The rules for the emancipation of a minor vary from state to state. Whilst in most cases court decision is required, in cases where the evidence shows that censurable parental conduct had occurred implied emancipation may apply (Legal Information Institute, n.d.). 


Protection of disclosure within the hospital 

Permitted uses and disclosures include the use of the individual’s name, location, and condition described in general terms to maintain the hospital’s directory and to be able to locate the individual in the facility. The patient should have the opportunity to agree or object to such disclosure [45 CFR 164.510(a)(1)(i)(A)-(C)]. In emergency circumstances, the health care provider shall act in the individual’s best interest as determined by the covered health care provider, in the exercise of professional judgment [45 CFR 164.510 (3)(B)]. 


Law enforcement disclosures 

The Fourth Amendment to the U.S. Constitution states: “The right of the people to be secure in their persons, houses, papers, and effects, against unreasonable searches and seizures, shall not be violated, and no warrants shall issue, but upon probable cause, supported by oath or affirmation, and particularly describing the place to be searched, and the persons or things to be seized” (U.S. Constitution, Amendment IV). Medical records contain very sensitive information about individual patients. Law enforcement searches are authorized as reasonable under very specific circumstances and only to a specific extent. Whilst the pregnancy could have been the result of a relationship between two sexually experimenting minors, the possibility that an adult was involved deserves an appropriate investigation. Successfully hiding a pregnancy from an immediate family is not an easy thing to achieve. Near-complete ignorance and willful blindness are required not to notice that a teen living in the same household is pregnant and about to give birth. Awareness of the pregnancy, in combination with the failure to provide appropriate support, could indicate the intent not to allow the infant to live. In some cultures, infants born from unapproved relationships are at risk of infanticide. 


The Site Privacy Officer shall make appropriate disclosures to staff in functions designated to coordinate high-risk cases of this nature with other appropriate departments and services, in addition to the investigation of the Breach. To this end, additional external disclosures may be necessary. A covered entity may use or disclose protected health information without the written consent or authorization of the individual if there is a reason to believe that the individual is a victim of abuse, neglect, or domestic violence. Such disclosure shall be limited in nature to comply with relevant laws if the individual agrees, or to the extent expressly authorized by statute or regulation [45 CFR 164.512 (c) (i) – (iii)]. Any attempts to mitigate the damage caused by the Breach shall be appropriately documented for the Office of Civil Rights (OCR).


Obligations after impermissible disclosures 

Once an impermissible disclosure has been made, covered entities should take steps to mitigate the potential damage. Covered entities have a duty to identify and document security incidents and privacy violations, including an impermissible disclosure. Appropriate safeguards include administrative, technical, and physical safeguards that protect PHI from any intentional or unintentional use or disclosure [45 CFR 164.530]. In response to the incident, the hospital should examine the events that led to the disclosure. This primarily includes the review of the history of impermissible uses and breach logs, training materials, and training records. Gap analysis and holistic vulnerability assessment to prevent future breaches would be beneficial to prevent future breaches. Examination and review of the hiring process and critical assessment of organizational culture would facilitate the change in the ways people think about patient privacy and the implications of privacy breaches. 


Personal accountability

The hospital shall have in place written policies and procedures regarding breach notification and must train their workforce appropriately. The organization also has to apply appropriate sanctions against staff members who fail to comply with HIPAA law as relevant to them. A breach of this kind would warrant the review of the appropriateness of policies and procedures, the record of previous breaches, and certainly a revision of training including a reminder of the implications of such disclosures for the patients and for the hospital. 


When hiring new people, the focus on technical skills shall not overshadow the importance of character, trustworthiness, and ethical conduct. Although most organizations perform background checks prior to hiring them, these do not typically reveal elements such as trust. Workforce retention is a major problem in healthcare. Recent estimates placed the cost of staff turnover at $40,000 to $80,000 per nurse, including the investment required to find a permanent replacement, ensure staffing of shifts and provide onboarding training (Cohen, 2013). 


A departing nurse can cause significant damage to the hospital, especially if hurt feelings are involved or the dismissal is perceived as unjust. Experience from the University of Rochester Medical Center (Shaw, 2016), shows how much damage a nurse can inflict on the hospital before leaving if she decides to take advantage of access to patient records that would give her the necessary leverage to either move to a new position or start a practice on her own (Shaw, 2016). 


Whether the nurse who caused the Breach should be dismissed is a decision, the Human Resources department would have to make. Considering the potential damage caused both to the patient and to the hospital, and the need for extensive resources dedicated to mitigation of the disclosure, immediate dismissal seems appropriate. The incident does violate not only HIPAA but also represents a breach of the professional code of conduct and hospital policies. Most importantly, it shows a lack of sound judgment, which may be critical in many other situations. However, any action taken by the hospital should be proportionate and fair to avoid scapegoating of a single individual for conduct that may, in fact, be a widespread cultural problem observable across the enterprise, especially when it is clear this was the result of a mishap rather than malicious intent. A careful review of past incidents, policies, and procedures and quality of training and training records should provide better guidance about what is appropriate. The hospital should also look into the use of personal devices for work and the use of encryption for short communications within the hospital. At the very least, the nurse should be placed on administrative leave until the investigation is closed. 


HIPAA v. the hospital 

The risks to the hospital include a liability relating to HIPAA compliance failure and tort claims, including negligence. HIPAA breaches and the implications resulting from compliance failure is not the only liability the hospital’s leadership could face. 

In 2012, in R.K. v. St. Mary’s Medical Center, the West Virginia Supreme Court of Appeals ruled that HIPAA did not preempt state law, and provided the standard of care for tort claims. The hospital shared R.K.’s medical information relating to his psychiatric hospitalization with his estranged wife, despite the patient’s request not to. R.K’s cause of action included negligence (R.K. v. . St. Mary’s Medical Center, 2012). 


In Byrne v. Avery Center for Obstetrics and Gynecology, the Connecticut Supreme Court ruled that HIPAA does not preempt negligent claims for a breach of patient privacy. In this particular case, Emily Byrne’s medical information was shared with her partner against her wish. The healthcare provider received a subpoena from her partner’s attorney in a paternity suit and complied with the request, disclosing Byrne’s medical information to her significant other. Byrne then successfully sued the hospital for negligence (Byrne v. Avery Center for Obstetrics and Gynecology, 2014). Lewis in The National Law Review (2014) stressed that the fact that HIPAA does not give patients a right of private action does not mean that remedies for questionable disclosures do not exist. Remedial measures include namely state health laws and common law torts (Lewis, 2014). 


Conclusion 

Disclosure of protected health information in circumstances that would make the individual subject to serious repercussions is a major concern for the affected individual and for the hospital. The incident represents a complex set of medical, legal and ethical concerns in addition to HIPAA violations. Professional judgment is required to decide whether or not there is a reason to believe the teen may have been the victim of abuse, neglect or domestic violence, whether the hospital can deny disclosure of the patient’s PHI to her parents, and whether implied emancipation applies in this case. Hospital’s post-incident assessment shall address the risk of harm to the affected patient and her infant child, review previous instances of improper disclosures and breaches, implement corrective and preventative action to ensure HIPAA compliance, and address other risks, such as the risk of litigation for negligence. The Human Resources Department shall make the decision about the nurse’s future employment, and place her on administrative leave until the completion of the investigation. Gap analysis and critical assessment of organizational culture would be beneficial to identify vulnerabilities in the hospital’s operations and address them appropriately. Policies and procedures have to be implemented with fidelity to be effective. Review of training materials, procedures, methodologies, and training effectiveness has to follow to prevent inadvertent disclosures in the future. Dismissal of a single employee does not solve the problem of systemic issues and organizational culture that need to be addressed separately to be effective. 

References

ASHG. (2015). ASHG Position Statement Provides Guidance for Genetic Testing in Children and Adolescents. Retrieved April 04, 2017, from https://www.genomeweb.com/molecular-diagnostics/ashg-position-statement-provides-guidance-genetic-testing-children-and 

Cohen, S. (2013). Recruitment and retention. OR Nurse,7(3), 8-10. doi:10.1097/01.orn.0000429410.21897.75

Gabler , E. (2013). Delays at hospitals across the country undermine newborn screening programs, putting babies at risk of disability and death. Retrieved April 04, 2017, from http://archive.jsonline.com/watchdog/watchdogreports/Deadly-Delays-Watchdog-Report-Delays-at-hospitals-across-the-country-undermine-newborn-screening-programs-putting-babies-at-risk-of-disability-and-death-228832111.html

Helba, C., Bernstein, M., Leonard, M., & Bauer, E. (2014). Report on Exploratory Study into Honor Violence Measurement Methods (Rep. No. 248879). Westat. 

HIPAA Privacy Rule Requirements Overview. (2003). The Practical Guide to HIPAA Privacy and Security Compliance. doi:10.1201/9780203507353.ch5

Josephson , J. J. (2016). Rethinking sexual citizenship. Albany: State University of New York Press . 

The Damaging Effects Of Shaming Teen Mothers. (2016, May 31). Retrieved April 04, 2017, from https://www.theodysseyonline.com/damaging-effects-shaming-teen-mothers 

Journeyman Pictures. (2016). Infanticide in Eastern Europe (1999) Retrieved April 04, 2017, from https://www.youtube.com/watch?v=ZjSC1xiQd-Q 

Legal Information Institute. (2007). Emancipation of Minors. Retrieved April 04, 2017, from https://www.law.cornell.edu/wex/emancipation_of_minors 

Lewis, J. (2014). Negligence Claims for Breach of Patient Privacy Not Preempted by HIPAA, Connecticut Supreme Court Holds. Retrieved April 04, 2017, from http://www.natlawreview.com/article/negligence-claims-breach-patient-privacy-not-preempted-hipaa-connecticut-supreme-cou 

National Institutes of Health. (2015). Preliminary Guidance Related to Informed Consent for Research on Dried Blood Spots Obtained Through Newborn Screening. Retrieved April 04, 2017, from https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-127.html 

Providertech (2020): 5 HIPAA Rules Regarding Text Messaging. ProviderTech. Retrieved Sep 28, 2020, from https://www.providertech.com/5-hipaa-rules-regarding-text-messaging/

RAINN. (n.d.). Children and Teens: Statistics . Retrieved April 04, 2017, from https://www.rainn.org/statistics/children-and-teens 
R.K. v. St. Mary's Medical Center, 735 S.E.2d 715 (2012) 229 W.Va. 712 (November 15, 2012). 

Secretary, H. O. (2013). Breach Notification Rule. Retrieved April 04, 2017, from https://www.hhs.gov/hipaa/for-professionals/breach-notification/index.html?language=es 

Whelan, A. M. (2013). That's My Baby: Why the State's Interest in Promoting Public Health Does Not Justify Residual Newborn Blood Spot Research Without Parental Consent. Minnesota Law Review ,98, 419-453. doi:10.2139/ssrn.2590100 

Secretary, H. O. (2015, November 05). Privacy Rule Introduction. Retrieved March 25, 2017, from https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/introduction/index.html

Shaw, G. (2016). Departing Nurseʼs HIPAA Breach Spurs New Privacy Policies at URMC — A Case In Point for Reviewing and Tightening Practices. Neurology Today,16(3), 11-12. doi:10.1097/01.nt.0000480943.34345.44

Warren, Z. (2014). Connecticut Supreme Court rules that HIPAA does not preempt negligence claim. Retrieved April 04, 2017, from http://www.insidecounsel.com/2014/11/11/connecticut-supreme-court-rules-that-hipaa-does-no?slreturn=1491315877 

Jak zlepšit odolnost firmy: Řízení rizik vyplývajících z vypršení platnosti certifikátů MDD
By Veronika Valdova 13 Nov, 2022
Nařízení (EU) 2017/745 o zdravotnických prostředcích vstoupilo v platnost 26. května 2021. Platnost certifikátů vydaných podle stávajících směrnic vyprší nejpozději 24. května. Toto je třeba provést ve lhůtě, která odpovídá době nezbytné pro přezkoumání dokumentace a před vypršením platnosti současných certifikací. Česká republika stále nemá svůj oznámený subjekt. Jakmile dojde k akreditaci, bude ITC zavalen ohromným počtem nevyřízených podání v českém jazyce. Zajisdtěte si pomoc s podáním od týmu Arete-Zoe, který má s přípravou klinické dokumentace dle MDR bohaté zkušenosti.
By Veronika Valdova & Ronald Sheckler 05 Nov, 2022
The reduction of Czech-based Notified Bodies (NBs) leaves only one still pending accreditation and one in Slovakia that does accept submissions in Czech. The delay in accreditation has produced a significant backlog for submissions pending review and acceptance. The complexity of MDR is more stringent both for the preparers and the reviewers at the NB. This situation introduces many vulnerabilities into the submission process and represents substantial risk that can and should be minimized! The potential consequences of certification delays may be critical for some manufacturers. Is the cost penalty from delay because of necessary revision or rejection worth the minor economy of an in-house effort? Get your staff an assessment from a team with proven MDR success! Contact Arete-Zoe for a courtesy review of your situation and secure assistance that will reduce your risk! Stay agile, competitive, and profitable! What is the current situation? Regulation (EU) 2017/745 on medical devices (the Medical Device Regulation, MDR), which was adopted in April 2017, became applicable in the European Union on 26 May 2021, after a year delay due to Covid [i] . The certificates issued under the existing Directives for medical devices ( 93/42/EEC and 90/385/EEC ) will expire on or before May 24th, 2024. By then, all manufacturers who wish to keep their products on the market as medical devices, will have to upgrade their documents to the new standards. Previous documentation standards fall far short to the new requirements, placing significant burden on both the manufacturers and reviewers at the NB. Many previous submissions under MDR have been rejected based on documentation shortfalls within any of the many sections. When considered with the significant backlog, any aspect of documentation that requires revision only compounds certification delay and may jeopardize market access for many medical devices. All this needs to be done within a period that accounts for the time necessary for review prior to expiration of current certifications. Additionally, there is a significant bottleneck in submission processing due to the limited capacity of NBs in the EU due to a reduction in the number of designated NBs, increased number of products that are subject to review by NB due to reclassification, and increased complexity of MDR submissions compared to MDD/AIMD. The Czech Republic still does not have its own designated NB. Once accreditation occurs, the backlog of Czech language submissions will be overwhelming. The high number of returns and requests for amendments and revisions shall be expected in the initial months, slowing the process further for all. By May 2024, many manufacturers will find themselves in a situation when their products will no longer be marketable in the EU due to expired certificates and face additional consequences from having products purged from supply chain. Discussion MDR is here to stay. Czech Minister of Health MUDr. Vlastimil Válek in his introductory statement at the October 2022 AVDZP Conference [ii] stated that another postponement of MDR is out of question. While it is not in the interest of the European Union to be dominated by non-EU manufacturers, primarily from Asia, it is unlikely that the existing Regulation will be substantially changed to accommodate manufacturers’ concerns. Válek also reminded the public that the Wild East mentality with improvised devices throughout the hospital system that dominated the Czech market in the 1990s is gone and will not return. In short, MDR is a reality to which manufacturers will have to adjust. Notified bodies available to Czech manufacturers under MDR The number of EU NBs that are designated under MDR has increased to 34, half of which are located in Italy (9) and Germany (8). The remaining 17 are in Belgium (1), Croatia (1), Finland (2), France (1), Hungary (1), Ireland (1), the Netherlands (3), Norway (1), Poland (2), Slovakia (1), Slovenia (1), Spain (1) and Sweden (1) [iii] . European manufacturers can pursue certification of their products with any EU NB, with limitations to the type of product and the capacity and willingness of NBs to take on new clients. However, for access to the greatest number of NBs, the submission should be in English. Two Czech NBs were designated in Czechia under the 93/42/EEC (MDD): Institut pro testování a certifikaci, a.s. (ITC) and Elektrotechnický Zkušební Ústav, s.p. (EZÚ). Only one of them, ITC, is in the process for designation under MDR. However, the final scope of MDR codes ITC will be able to process has not been released. One additional institution, Czech Metrological Institute (CMI) is pursuing designation under MDR without prior history in medical devices under MDD or AIMD. The anticipated accreditation will take an additional year. Institut pro testování a certifikaci, a.s. (ITC), Czech Republic ITC’s current designations include Regulation (EU) 2016/425 Personal protective equipment, 2014/68/EU Pressure equipment, 2009/48/EC Safety of toys, Regulation (EU) No 305/2011 - Construction products and 2014/30/EU Electromagnetic compatibility. Designations under 93/42/EEC Medical devices and 98/79/EC In vitro diagnostic medical devices expired in May 2021 (MDD) and May 2022 (IVDD) [iv] . ITC will continue to perform audits under MDD during the transitional period until May 24, 2024. ITC submitted their application for designation under MDR on December 30, 2019. The Designating authority (ÚNMZ) verified completeness of the application and forwarded it to the European Commission in November 2020. The Commission designated the Joint Assessment Team in December 2020, which completed the evaluated in March 2021. On-site Joint Assessment was completed in June 2021. The official JAT report was issued in September 2021. ITC implemented CAPAs in fall 2021. In June 2022, designating authority ÚNMZ completed their review of CAPAs implemented by ITC and submitted it to the Joint Assessment Team for approval. In August 2022, ÚNMZ issued the final report. In September 2022, JAT issued its final assessment and a in October 23022, ITC underwent MDCG review and is now awaiting MDCG opinion that the notification can be accepted. The expectation is that ITC should be listed in the NANDO database by January 2023 for MDR [v] . According to Mgr. Jiří Heš, ITC will primarily serve Czech manufacturers who already are their clients and have certificates issued by them under MDD. New certificates under MDR won’t be issued in time and there will inevitably be a gap in coverage of products with valid MDD certification. [vi] ITC only began preparing application for designation under IVDR. Due to the extensive backlog of MDR certificates, it is reasonable to expect that the process of designation under IVDR will not be any faster. ITC currently does not offer any training on MDR for manufacturers or guidance on how to prepare submissions. The most significant thing any manufacturer can do for themselves is to ensure their submission is as appropriate as possible the first time. But they are left to their own means to sort out the transition from MDD to MDR. Without specific guidance from ITC on their expectations, there is significant risk from the ambiguity of the MDR Regulation itself. However, this risk can be reduced from experience from submissions under MDR to other NBs which will provide reasonable opportunity for a successful submission. Elektrotechnický Zkušební Ústav, s.p. (EZÚ), Czech Republic EZÚ’s current designations include Regulation (EU) No 305/2011 - Construction products and 2014/30/EU Electromagnetic compatibility. EZÚ won’t pursue designation under MDR. The activities EZÚ will continue include audit under MDD during the transitional period for 42 manufacturers whose certificates they serve, certification of quality management systems, and electrical safety. EZÚ also provides training on MDR for manufacturers and distributors [vii] . Czech Metrological Institute (CMI), Czech Republic CMI submitted their initial application in December 2020, a year later than ITC. The Joint Assessment Team evaluation (Article 39, paragraph 4 MDR) was completed in December 2021. In May 2022, CMI submitted their proposed CAPA plan. CMI strives to maintain the scope of devices included in their application (23 out of 44 basic codes and 18 out of 27 horizontal codes). The key requirement is to prove personnel availability for each code. CMI primarily intends to serve Czech manufacturers in Czech language, as only about a third of their reviewers have sufficient proficiency in English. CMI does not provide any training or guidance for manufacturers how to prepare documentation to pass their scrutiny. Certification of products on the Czech market There are over 400 Czech manufacturers listed in the database RZPRO holding nearly 6000 certificates that are currently valid. Of these, 4323 did not previously require the involvement of a NB (Class I). However, due to reclassification, some of these will require involvement of the NB under MDR, further stressing the throughput of the NB. Of the 1634 remaining certificates, 514 were issued by EZÚ and 391 by ITC. Another 133 MDD certificates were issued by other NBs that do not currently have MDR designation. The database also holds 2305 products other than Class I that do not have a NB listed. In total, ITC issued 541 certificates that are currently valid, including manufacturers from other countries. The database currently holds 630 valid certificates issued by EZÚ. All products certified by EZÚ will have to be recertified by another NB [viii] . The list of MDR codes that will be covered by ITC (or CMI, once designated) is not currently available. Mgr. Irena Storova (Czech State Institute for Drug Control) emphasized the quality of the MDR documentation as an essential condition required to avert a crisis. The current speed of issuing certificates by EU NBs is about 1.000 certificates a year. However, the anticipated need for medical devices in Europe is about 23.000 certificates issued by NBs over the period of 20 months, making the transition to MDR extremely challenging. The key problems are insufficient capacity of NB, partly due to accumulated backlog, partly due to increased complexity of MDR compared to MDD/AIMD, as well as inadequate preparedness of manufacturers to meet the new complex requirements of MDR [ix] . Experience of other EU NB shows exponential growth of applications and a serious lag in processing certificates. In February 2021, NBs received 1840 applications and processed 224 certificates. By October 2022, the number of applications grew to 8120, while the number of issued certificates was 1990 [x] . These numbers suggest further accumulation of backlog of unprocessed applications rather than catching up with the growing demand. The time to reach a Certificate according to MDR (MDR Quality Management System and Product certification) typically ranges from 13 to 18 months [xi] . This is consistent with ITC’s estimate that the review of a complete submission will take a year to issue a certificate. This means that all manufacturers who need their certificates renewed before the May 2024 deadline when they all expire will have to submit their applications before May 2023. Since ITC will only start accepting applications after the official MDR designation, it is safe to assume that all applications will be submitted in the period between the designation date and May 2023, creating a long backlog queue. To complicate the situation even further, manufacturers, whose MDR codes won’t be on ITC’s list, will have to look for a different NB to pursue their certificates. Czechia as a low price-point market The low-price level of devices on the Czech market complicates the transition to MDR even further. The system of defining reimbursements for medical devices is very rigid, and there are multiple pressures that keep prices down. These price controls conflict with increased costs associated with certification and recertification of products when considered with increased costs of energy, raw materials, transport, and labor. MUDr. Vlastimil Válek at the AVDZP Conference on October 13, 2022, stated that it is not in the interest of the European Union to allow non-EU manufacturers to dominate the EU market, and that there is an intrinsic value in self-sufficiency in times of crisis [xii] . The results from Survey on certifications and applications performed by MDCG & Stakeholders among NBs (51 NBs asked, 47 replies received) suggest that 60% of medical device clients are non-EU (10,913), compared to 7,143 EU clients [xiii] . Priority treatment for small business is not likely since SMEs are the majority of NB clients, both EU-wide and locally in the Czech Republic. In fact, as the threat for shortage of medical equipment becomes more urgent, policymakers might solve the crisis by prioritizing producers with high capacity, capable of meeting the demands of their respective health systems, as we have seen with the imports of medical equipment and protective materials during the Covid crisis. What is the risk to business due to delays in certification? The ability of NBs to process applications in a timely manner is an essential condition for the function of the medical device sector. This is directly influenced by the quality of manufacturers’ submission for certification. Manufacturers cannot legally keep their products on the EU market without valid certification. And, additional expenses will be incurred, if products have to be recovered from distribution chains due to delays in certification. Furthermore, this will create gaps in coverage, creating a void that can be filled by competitors. Extended periods of absence can stall otherwise good products and limit marketability once certification is finally obtained. Failure to obtain MDR certification for any portion of a product portfolio is an existential threat to any enterprise, potentially forcing reduction of staff, downsizing, making the enterprise vulnerable to competitors, or simply losing viability and going out of business. The absence of a feedback loop regarding the minutia of submissions’ content and format will cause additional delays and adjustments by the industry. ITC does not provide any MDR training and did not issue any guidance documents to facilitate successful submissions and reduce ambiguity relating to the novelty of the process. The first MDR certificate was issued in September 2019 by BSI [xiv] . This means that the cumulative experience in the industry among competition is significantly higher, placing Czech manufacturers 4 years behind other EU players. At present, Czech manufacturers have to rely on training provided by other NBs, industry consultants who rely on the same, in addition to feedback from their clients, and their own understanding of the Regulation and associated MDCG guidelines. Although CzechInvest does have a plan to start a comprehensive training program for manufacturers to facilitate the transition to MDR, the course has not started yet. The first students are expected to graduate in June 2024 [xv] . Learning curve by both newly designated NBs as well as manufacturers will inevitably affect the speed of processing, forcing reworks and amendments that would otherwise be avoidable. Securing consultancy with demonstrated MDR competency will remove substantial risk from the current situation. Recommendations What is the risk, and how does Arete-Zoe help your enterprise to mitigate such risk? The key to a successful MDR certification is a high quality, timely submission that complies with or better, exceeds minimum MDR requirements, ensuring timely processing and avoiding returns, requests for more information and outright rejections. It is important to note that the review and approval process depends on the understanding and application of MDR requirements by individual reviewers. Therefore, exceeding minimum requirements becomes a necessity for confident approval. The impact of additional information requests, although minor in terms of extra work, can be significant due to delays. Additionally, other manufacturers’ failed submissions in a long backlog of applications will continue to burden the system. The quality of the initial submission is essential to avoiding consequences in the transition to MDR and may be the single factor that keeps the business open. Manufacturers who have a fully trained in-house team already should still expect challenges in preparing MDR submissions themselves. The time to develop MDR expertise is very limited, considering the pressure to prepare the full documentation and submit it before May 2023. Even with a well-staffed team, the task can simply be overwhelming due to the sheer volume of material required in contrast to previous MDD/AIMD submissions. Arete-Zoe team has significant experience preparing clinical documentation for clients transitioning from MDD to MDR in both Czech and English and submissions through multiple NBs. Our exceptional success record with clinical documentation includes products that were previously rejected but passed with our assistance. We can help control the risk of failure or delay for our clients by providing the essential support you need to avert a avoidable delays in product certification. Arete-Zoe team can either prepare the full submission or augment your existing team with essential skillset your team might not have. References [i] https://www.ema.europa.eu/en/news/medical-device-regulation-comes-application [ii] Válek, V (2022). Introduction. AVDZP Conference 13/10/2022, Praha, Czech Republic. [iii] NANDO database https://ec.europa.eu/growth/tools-databases/nando/index.cfm?fuseaction=directive.notifiedbody&dir_id=34 [iv] NANDO database https://ec.europa.eu/growth/tools-databases/nando/index.cfm?fuseaction=directive.notifiedbody&dir_id=34 [v] Heš, J (2022). Implementace MDR: Kde jsme a kam směřujeme. AVDZP Conference 13/10/2022, Praha, Czech Republic. Institut pro Testování a Certifikaci. [vi] Heš, J (2022). Implementace MDR: Kde jsme a kam směřujeme. AVDZP Conference 13/10/2022, Praha, Czech Republic. Institut pro Testování a Certifikaci. [vii] Vlasák, M (2022). Dozorová činnost dle MDD. AVDZP Conference 13/10/2022, Praha, Czech Republic. Elektrotechnický zkušební ústav. [viii] Czech database of medical devices RZPRO https://eregpublicsecure.ksrzis.cz/Registr/RZPRO/ZdravotnickyProstredek [ix] Storova, I (2022). Problematika ukončení přechodného období MDR z pohledu SÚKL. AVDZP Conference 13/10/2022, Praha, Czech Republic. State Institute for Drug Control. [x] MDCG & Stakeholders (2022). Notified Bodies Survey on certyifications and applications (MDR/IVDR). 24/10/2022. European Commission. [xi] MDCG & Stakeholders (2022). Notified Bodies Survey on certyifications and applications (MDR/IVDR). 24/10/2022. European Commission. [xii] Válek, V (2022). Introduction. AVDZP Conference 13/10/2022, Praha, Czech Republic. [xiii] MDCG & Stakeholders (2022). Notified Bodies Survey on certifications and applications (MDR/IVDR). 24/10/2022. European Commission. https://health.ec.europa.eu/latest-updates/notified-bodies-survey-certifications-and-applications-2022-10-26_en?fbclid=IwAR3w3YH7UD2HBccQ6pBKWP3UlpgSnvQj9qFoNUeLIF-6ZWl8IOwP2Wx88Tk [xiv] BSI (2019). BSI certifies first product to the Medical Devices Regulation. 02 September 2019. BSI. https://www.bsigroup.com/en-GB/medical-devices/news-centre/enews/2019-news/bsi-certifies-first-product-to-the-medical-devices-regulation/ [xv] Hájek, J (2022). Národní plán obnovy. Komponenta 1. 4. Digitální ekonomika a společnost, inovativní start-upy a nové technologie. Program na podporu specifických systémových a produktových certifikací a souvisejícího vzdělávání. AVDZP Conference 13/10/2022, Praha, Czech Republic.
By Veronika Valdova 21 Jun, 2022
History of EU device legislation, definitions, obligations of economic subjects
By Veronika Valdova 21 Jun, 2022
Introduction & Orientation
By Veronika Valdova 28 May, 2022
More than 500,000 medical technologies are available on the European market, from hospitals to community care settings and people's homes. The products range from syringes, pregnancy tests, and wheelchairs to X-Ray machines and body scanners, pacemakers, hip implants, and pharmacogenomic tests. The medical technology industry is the source of a constant flow of innovations. The sector spends about 8% of its sales on R&D. Typical product lifecycle is about 18 to 24 months when a new, improved version becomes available. In 2020, the European Patent Office (EPO) accepted nearly 14,200 patent applications in the medical technology sector, trumping pharmaceutical patents (8,500 applications) and biotechnology (7,200). European and U.S. entities filed almost 80% of the applications (38% EU and EEA, 39% U.S.) [ 1 ]. The European medical technology sector employs more than 760,000 people, mainly in Germany (210,000), the United Kingdom (102,800), Italy (94,000), France (89,000), Switzerland (63,000), and Ireland (40,000), accounting for 0.3% of total employment. In comparison, the European pharmaceutical industry employs around 795,000 people. These jobs reach a value-added of about €184,000 per employee. More than 33,000 medical technology exist in Europe, of which 95% qualify as small, medium, and micro-sized companies (SMEs). The majority of these enterprises employ less than 50 people [ 1 ]. In 2020, Europe had a positive trade balance in the medical technology sector of € 8.7 billion. Compared to 2019, the European trade balance dropped by 27.5% (€ 12 billion in 2019). The most important trading partners for Europe are the United States, China, Japan, and Mexico. Germany, Ireland, the Netherlands, Belgium, and Switzerland have the highest trade share, both within and outside the EU [ 2 ]. Until May 2021, the medical device sector was regulated by Medical Device and In Vitro Diagnostic Device Directives 93/42/EC and 90/385/EEC (MDD and IVDD), when the new Regulations replaced these: Medical Device Regulation (EU) 2017/745 (MDR) and In Vitro Diagnostic Device Regulation (IVDR) 2017/746 [ 3 ],[ 4 ]. The new regulations introduced numerous changes, including the reclassification of some devices, requiring additional obligations for manufacturers to comply with. About 85% of in-vitro diagnostic devices will now require Notified Body involvement, compared to ~20% under the IVDD. Existing MDD/IVDD certificates remain valid until May 2024. After this date, all devices on the EU market must comply with the new MDR/IVDR regulations [ 5 ]. For some manufacturers, the costs associated with keeping some of their devices on the market under MDR/IVDR may no longer justify the expense considering their profitability. Others may not be able to obtain new CE Mark certification in time due to decreased capacity of notified bodies. These factors combined are already reducing the number of devices on the EU market and limiting the certification of innovative products. The number of notified bodies available to review new certifications and recertifications dropped significantly under the MDR/IVDR. Of 51 notified bodies designated to MDD [ 6 ] and ten to AIMDD [ 7 ], only 29 obtained designation for MDR, of which seven operate in Germany, seven in Italy, and three in the Netherlands [ 8 ].
By Veronika Valdova 28 May, 2022
The Medical Device industry produces a vast number of products, ranging from bandages and surgical instruments to life function monitors to imaging technology. The technology currently in use varies from devices that have been in use for decades to highly innovative products. Innovations in the medical device field are frequent and typically incremental in response to feedback from physicians. Mordor Intelligence estimated the global Medical Devices market at USD 532.62 billion in 2021, growing at a CAGR of around 5.5%, to reach USD 734.39 billion in 2027 [1]. Fortune Business Insights projects the global medical devices market growth from $455.34 billion in 2021 to $657.98 billion in 2028 at a CAGR of 5.4%. This development follows a decline from 2020, when CAGR dropped to 3.7% due to the pandemic [2]. The key drivers of market growth include the rising prevalence of chronic diseases, increased disability throughout the population, technological advancements in medical devices, and population aging. The U.S. medical device market was valued at USD 186.5 billion in 2021 and is anticipated to exhibit a compound annual growth rate (CAGR) of 5.0% over the forecast period to reach USD 262.4 billion in 2028 [4]. The Medical Device sector is even larger than Biopharmaceuticals, that by comparison, employed over 224,000 people, earning $21.2 billion [3]. The rising prevalence of chronic diseases and the increasing geriatric population in the country are the key market drivers. The Medical Device industry has a significant impact on the U.S. economy and supports hundreds of thousands of jobs. More than 80 percent of U.S. medical device companies have fewer than 100 employees [5]. In 2020, the U.S. Medical Device industry supported over 329,000 jobs, with an annual payroll of $25.8 billion [3]. Employment and payroll for Medical Device Subsectors, 2020 ( SelectUSA ):
By Veronika Valdova & Ronald L Sheckler 28 Sep, 2021
U.S. Pharmaceutical Dependency on Foreign Sole-Source Production of Essential Materials Imposes Vulnerable Exposure to Interruption by Both Natural and Man-Made Threats
The business case for more robust pre-clinical research
By Veronika Valdova 13 Feb, 2020
In the high consequence environment of pharmaceutical development, any assumption made earlier in the process can prove extremely costly if uncorrected once more information becomes available. From a business perspective, it is essential to create a safe avenue for communication of concerns regarding the drug candidate’s efficacy, safety, toxicity, or pharmacological function immediately as the researchers become aware of them.
Occam's Razor
By Veronika Valdova 13 Feb, 2020
Innovation always involves the risk of failure. It is an art to see what the data show, and what they don't, and which projections are the result of our wishful thinking or unsubstantiated assumptions. It may be just my impression that 14th-century logician William of Ockham whispers in my ear that entities shall not be multiplied unnecessarily.
Training improves organizational resilience, even in pharma.
By Veronika Valdova 13 Feb, 2020
Companies are growing in size due to acquisitions and mergers. Operations routinely span across geographical, jurisdictional, and cultural boundaries. The trend of industry consolidation continues in 2015 and 2016: the total number of deals flattened and remained even at around 600 mergers a year. Geographically, mergers, and acquisitions have been shifting from the U.S. to Western Europe. This shift is the result of transactions driven by the need to add complementary products to the core business areas and tax inversions.
More Posts
Share by: